Home > Article

Premarket Roundup: Immucor, Crocs

By Associated Press

April 2, 2008

Recommended (0)

Among the premarket activity stories for Wednesday, April 2, from AP Financial News:

NEW YORK (AP) _ Immucor shares are rising in premarket trading after the blood-testing equipment maker reported strong fiscal third-quarter results.

NEW YORK (AP) _ Shares of Crocs Inc. declined in Wednesday premarket trading after a JPMorgan analyst downgraded shares of the colorful plastic shoe company on weaker-than-expected U.S. sales.

NEW YORK (AP) _ The Talbots Inc.'s turnaround is taking hold and will help drive long-term growth for the women's apparel retailer, according to several analysts.

NEW YORK (AP) _ A Goldman Sachs analyst encouraged investors to stop trading shares of China Netcom Group Corp. and China Telecom Corp. Ltd. in tandem on Wednesday, as the distance between their values has fallen in recent months.

Comment (0)

Recommended (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

DocumentId: 612007, ~/articles/articlehandler.aspx, 10/11/2008 12:24:18 AM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement